A new UCL-led international trial will assess whether AI can perform as well as expert radiologists at detecting prostate ...

Only men with a dangerous genetic variant and a family history of cancer should be offered screening, say UK advisors.

New blood test could show if prostate cancer treatment is failing - The discovery could lead to personalised treatments for the disease ...

Tempus AI (NasdaqGS:TEM) has launched the ArteraAI Prostate Test, its first externally developed AI-powered digital pathology test for metastatic hormone-sensitive prostate cancer. The test is ...

Technologies combining MRI, robotics, and artificial intelligence are changing the way prostate cancer is diagnosed and ...

Government will consider committee’s guidance that says mass screening ‘likely to cause more harm than good’ ...

Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit ...

The Government’s plans for prostate cancer screening do not go far enough, experts have warned. James Murray, the new Health ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...

The UK Department of Health and Social Care has announced an additional investment of up to £18m, to extend the landmark ...

Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...